On execution, the company described building an integrated commercial organization supported by sales, medical affairs, nurse educators, field reimbursement specialists, and its CrinetiCARE nurse-staffed support program. Chief Commercial Officer Isabel Kalofonos said feedback is centering on efficacy and symptom control, and she noted physicians and patients are responding to the drug’s observed “patterns of action and the symptom controls,” including that it “works in two to four weeks.”Struthers said adop ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker14Welcome to Crinetics Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. At this time, all participants are in listen only mode. Following management's prepared remarks, we will hold a question and answer session. In order to ask a question, please press star then 1 on your telephone. I'd now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Pleas ...

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a gl ...

Core Insights - Crinetics Pharmaceuticals, Inc. will participate in two upcoming investor conferences, providing opportunities for 1x1 meetings with management [1][2] - The company focuses on transforming the treatment of endocrine diseases and related tumors through innovative therapies [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for acromegaly, with additional programs in development for various endocrine conditions [4] Group 1: Upcoming Events - Crinetics will attend the TD Cowen 46 Annual Health Care Conference in Boston on March 4, 2026, with a fireside chat scheduled for 1:50 p.m. Eastern Time [1] - Management will also be available for 1x1 meetings on March 4, 2026, and at the Leerink Annual Global Healthcare Conference in Miami on March 11, 2026 [1] Group 2: Company Overview - Crinetics Pharmaceuticals is dedicated to discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) [3] - The company has a pipeline of over 10 disclosed programs, including late-stage candidates for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs address various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 4:30 p.m. ET to discuss the results and provide a business update [1]. Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [4]. - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [4]. Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [5]. - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [5]. - The company has a deep pipeline of over 10 disclosed programs, including late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate for treating SST2 expressing neuroendocrine tumors and other solid tumors [5]. - Additional discovery programs target various endocrine conditions such as Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [5].

Core Insights - Crinetics Pharmaceuticals has initiated the BALANCE-CAH Phase 2/3 trial for atumelnant, a novel ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) in children and adolescents [1][2] Group 1: Study Overview - The BALANCE-CAH trial is designed to evaluate the safety, efficacy, and pharmacokinetics of atumelnant in pediatric patients with CAH, addressing a significant unmet medical need [2][3] - The study consists of three parts: Part A is a Phase 2 open-label dose-ranging study, Part B is a Phase 3 double-blind randomized placebo-controlled study, and Part C is an open-label extension [3] Group 2: Atumelnant Details - Atumelnant is the first and only small molecule ACTH receptor antagonist in late-stage clinical development, specifically targeting the melanocortin type 2 receptor (MC2R) to block excess androgen production [2][4] - Preclinical studies have shown that atumelnant has a strong binding affinity for MC2R and has demonstrated significant reductions in key CAH biomarkers, indicating its potential to transform care for individuals with CAH [4] Group 3: Company Background - Crinetics Pharmaceuticals focuses on developing novel therapies for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [5] - The company’s lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved for adults with acromegaly, and it has a robust pipeline of over 10 programs, including atumelnant [6]

Core Insights - Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is recognized as one of the top 14 booming stocks to buy currently, with Goldman Sachs upgrading its rating to Buy from Neutral and setting a price target of $67 [1][2] Group 1: Stock Ratings and Price Targets - Goldman Sachs analyst Richard Law upgraded CRNX to Buy from Neutral following positive trial results for atumelnant, which showed a 67% reduction in A4 in Cohort 4, consistent with earlier cohorts [2] - Citizens analyst Jonathan Wolleben slightly reduced the price target for CRNX to $105 from $108 while maintaining an Outperform rating [3] Group 2: Product Performance and Revenue - A survey of American endocrinologists indicated a 'positive early experience' with Crinetics' drug Palsonify for treating acromegaly, supporting a preliminary net product revenue of over $5 million for Q4 [4] - Citizens anticipates that Palsonify will continue to exceed expectations through 2026 [5] Group 3: Analyst Consensus and Market Outlook - Wall Street analysts maintain a bullish outlook on CRNX, with a consensus Strong Buy rating and a one-year average price target of $88.64, indicating an upside potential of 60.14% as of January 12 [5]

Crinetics Pharmaceuticals FY Conference Summary Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Date of Conference**: January 13, 2026 - **Key Speaker**: Scott Struthers, CEO Core Industry and Company Insights Achievements and Developments - **Palsinify Approval**: Received broad label approval for Palsinify for the treatment of acromegaly on its PDUFA date, marking a significant milestone for the company [3][7] - **Successful Launch**: The launch of Palsinify has been successful, with over 200 patients enrolled in the last quarter and more than 125 unique prescribers involved [8][9] - **Pipeline Expansion**: Positive phase two data reported for atumelnant, with ongoing phase three studies for carcinoid syndrome and new compound 9682 in phase one/two studies for neuroendocrine tumors (NETs) [3][4] Financial Position - **Funding**: The company has approximately $1.4 billion in the bank, providing a solid foundation for operations through 2030 [4] - **Revenue Generation**: Achieved over $5 million in revenue last year, with expectations for growth as Palsinify gains market acceptance [11] Patient Engagement and Market Strategy - **Patient Services**: Implemented a comprehensive patient services program, including a Quick Start program to facilitate access to Palsinify [10][13] - **Market Access**: Focus on expanding prescriber base and activating patients who have previously settled with their conditions [34][35] - **Payer Engagement**: Strong efforts to communicate the value of Palsinify to payers, with CVS Caremark covering over 27 million lives [36][38] Pipeline and Future Prospects Palsinify and Acromegaly - **Market Potential**: There are approximately 36,000 patients with acromegaly in the U.S., with only 3,000 currently on standard care, indicating significant room for growth [14][15] - **Blockbuster Potential**: The CEO expressed confidence that Palsinify could become a blockbuster drug, aiming to help more than 5,000 patients per $1 billion in revenue [15] Atumelnant and CAH - **Clinical Development**: Atumelnant is positioned as a treatment for congenital adrenal hyperplasia (CAH), with promising phase two data showing significant reductions in adrenal androgens [20][25] - **Patient Population**: Approximately 12,000 patients in the U.S. are affected by CAH, with a focus on achieving normal hormone levels through treatment [25] 9682 and Neuroendocrine Tumors - **New Platform**: 9682 is being developed as a drug targeting agent for SST2-positive expressing solid tumors, with a phase 1/2 trial currently underway [27][28] - **Market Opportunity**: There are 11,000-21,000 patients currently treated for neuroendocrine tumors, with many more not receiving treatment [28] Key Milestones and Future Outlook - **2030 Vision**: The company aims to emerge as a premier endocrinology business with two marketed products and four approved indications by 2030 [30] - **Clinical Pipeline**: Anticipates having seven clinical pipeline candidates in development, with ongoing investments in discovery labs [30] Additional Insights - **Patient-Centric Approach**: Emphasis on patient stories and experiences to enhance engagement and support for Palsinify [12][13] - **Regulatory Strategy**: The company is actively monitoring and managing clinical trials to ensure high-quality data and compliance [45][46] This summary encapsulates the key points from the Crinetics Pharmaceuticals FY Conference, highlighting the company's achievements, pipeline developments, financial position, and strategic outlook for the future.

Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].